| scholarly article | Q13442814 |
| P50 | author | Pravin Patel | Q57014429 |
| Jan Ryerse | Q115615195 | ||
| P2093 | author name string | Yasuyuki Suzuki | |
| Shunji Tomatsu | |||
| Tadao Orii | |||
| Eriko Yasuda | |||
| Barbara Nagel | |||
| Tsuyoshi Takami | |||
| Jozef Zustin | |||
| Tsutomu Shimada | |||
| Kenji E Orii | |||
| William Mackenzie | |||
| Katsuji Shimizu | |||
| Mary Theroux | |||
| Hiroki Iida | |||
| Kazunari Fushimi | |||
| Kristen Ruhnke | |||
| Bobbie Boyce | |||
| Carol Barone | |||
| Terry Kokas | |||
| P2860 | cites work | Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA | Q30537233 |
| Skeletal dysplasias: evaluation with impulse oscillometry and thoracoabdominal motion analysis | Q35917712 | ||
| Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment | Q37867134 | ||
| Neuronal Cytoplasmic Globules in the Brain in Morquio's Syndrome | Q43682466 | ||
| Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease | Q44635437 | ||
| Deficiency in N-acetylgalactosamine-6-sulfate sulfatase results in collagen perturbations in cartilage of Morquio syndrome A patients. | Q46036993 | ||
| Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase | Q46747931 | ||
| Anesthetic care and perioperative complications of children with Morquio syndrome | Q48151553 | ||
| Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins | Q48169854 | ||
| International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. | Q51762816 | ||
| Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA. | Q52005459 | ||
| A molecular and histological characterization of cartilage from patients with Morquio syndrome | Q56994311 | ||
| Sacral dimple: incidental findings from newborn evaluation. Mucopolysaccharidosis IVA disease | Q57646236 | ||
| Fetal presentation of Morquio disease type A | Q67471346 | ||
| Morquio disease: The role of cartilage canals in the pathogenesis of chondrogenic dwarfism | Q84963041 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 301-311 | |
| P577 | publication date | 2013-04-16 | |
| P1433 | published in | Molecular Genetics and Metabolism | Q6895949 |
| P1476 | title | Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder | |
| P478 | volume | 109 |
| Q90403730 | Abnormally increased carotid intima media-thickness and elasticity in patients with Morquio A disease |
| Q37243265 | Activity of daily living for Morquio A syndrome. |
| Q59340094 | Anesthesiological risks in mucopolysaccharidoses |
| Q30367116 | Aortic Root Dilatation in Mucopolysaccharidosis I-VII |
| Q61799365 | Biomarkers in patients with mucopolysaccharidosis type II and IV |
| Q36586241 | Bone mineral density in MPS IV A (Morquio syndrome type A). |
| Q49847145 | Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase Alfa |
| Q37624919 | Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness |
| Q34459501 | Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII. |
| Q33721971 | Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa. |
| Q37646091 | Current therapies for Morquio A syndrome and their clinical outcomes |
| Q35752500 | Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB. |
| Q33747881 | Diagnosis of Morquio-A patients in Mexico: How far are we from prompt diagnosis? |
| Q38286451 | Diagnostic evaluation, monitoring, and perioperative management of spinal cord compression in patients with Morquio syndrome. |
| Q34389992 | Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study |
| Q38794433 | Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome). |
| Q94355134 | Enzyme replacement therapy for mucopolysaccharidosis type IV (Morquio syndrome) |
| Q36677856 | Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. |
| Q34633246 | Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions? |
| Q90720527 | Enzyme-Loaded Gel Core Nanostructured Lipid Carriers to Improve Treatment of Lysosomal Storage Diseases: Formulation and In Vitro Cellular Studies of Elosulfase Alfa-Loaded Systems |
| Q36127763 | Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome) |
| Q27318642 | Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I |
| Q35319254 | Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome. |
| Q37341874 | Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome. |
| Q34938821 | Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. |
| Q88741300 | Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA |
| Q26824085 | Morquio A syndrome-associated mutations: a review of alterations in the GALNS gene and a new locus-specific database |
| Q89769208 | Morquio-B disease: Clinical and genetic characteristics of a distinct GLB1-related dysostosis multiplex |
| Q37626886 | Mucopolysaccharidosis IVA and glycosaminoglycans. |
| Q89895108 | Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management |
| Q47658772 | Natural history of Morquio A patient with tracheal obstruction from birth to death |
| Q36445773 | Non-invasive pulmonary function test on Morquio patients |
| Q57302052 | Non-invasive pulmonary function test on Morquio patients |
| Q36586406 | Obstructive airway in Morquio A syndrome, the past, the present and the future. |
| Q89272230 | Outcomes from 18 years of cervical spine surgery in MPS IVA: a single centre's experience |
| Q34789123 | Overcoming the barriers to diagnosis of Morquio A syndrome |
| Q34891119 | Paraplegia after epidural-general anesthesia in a Morquio patient with moderate thoracic spinal stenosis |
| Q54191084 | Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study. |
| Q37729304 | The Carotid Intima-Media Thickness and Arterial Stiffness of Pediatric Mucopolysaccharidosis Patients Are Increased Compared to Both Pediatric and Adult Controls |
| Q26852308 | Therapies for the bone in mucopolysaccharidoses |
| Q34545883 | Therapies of mucopolysaccharidosis IVA (Morquio A syndrome). |
| Q26746227 | Unique medical issues in adult patients with mucopolysaccharidoses |
| Q47136951 | Widespread Vasculopathy in a Patient with Morquio A Syndrome |
Search more.